Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Denize

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Nature Cell Biology|August 17, 2023
KDM6A epigenetically regulates subtype plasticity in small cell lung cancerLeslie Duplaquet, Yixiang Li, Matthew A Booker, et al.
Nature|September 4, 2024
A pathology foundation model for cancer diagnosis and prognosis predictionXiyue Wang, Junhan Zhao, Eliana Marostica, et al.
Cancer Immunology Research|June 6, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell CarcinomaRenee Maria Saliby, Talal El Zarif, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trialNourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.
Cancer Cell|March 12, 2021
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinomaKevin Bi, Meng Xiao He, Ziad Bakouny, et al.
Cancer Discovery|February 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell CarcinomaMiya B Hugaboom, Lena V Wirth, Kelly Street, et al.
Cancer Cell|June 10, 2025
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinomaKevin Bi, Meng Xiao He, Ziad Bakouny, et al.
Journal for Immunotherapy of Cancer|April 20, 2025
Reversible downregulation of HLA class I in adenoid cystic carcinomaAnnie Li, Bianca L Gonda, Elizabeth M Codd, et al.
Nature Communications|January 21, 2023
Epigenomic charting and functional annotation of risk loci in renal cell carcinomaAmin H Nassar, Sarah Abou Alaiwi, Sylvan C Baca, et al.
Cancer Cell|March 12, 2021
Progressive immune dysfunction with advancing disease stage in renal cell carcinomaDavid A Braun, Kelly Street, Kelly P Burke, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Nature Cell Biology|August 17, 2023
KDM6A epigenetically regulates subtype plasticity in small cell lung cancerLeslie Duplaquet, Yixiang Li, Matthew A Booker, et al.
Nature|September 4, 2024
A pathology foundation model for cancer diagnosis and prognosis predictionXiyue Wang, Junhan Zhao, Eliana Marostica, et al.
Cancer Immunology Research|June 6, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell CarcinomaRenee Maria Saliby, Talal El Zarif, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trialNourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.
Cancer Cell|March 12, 2021
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinomaKevin Bi, Meng Xiao He, Ziad Bakouny, et al.
Cancer Discovery|February 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell CarcinomaMiya B Hugaboom, Lena V Wirth, Kelly Street, et al.
Cancer Cell|June 10, 2025
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinomaKevin Bi, Meng Xiao He, Ziad Bakouny, et al.
Journal for Immunotherapy of Cancer|April 20, 2025
Reversible downregulation of HLA class I in adenoid cystic carcinomaAnnie Li, Bianca L Gonda, Elizabeth M Codd, et al.
Nature Communications|January 21, 2023
Epigenomic charting and functional annotation of risk loci in renal cell carcinomaAmin H Nassar, Sarah Abou Alaiwi, Sylvan C Baca, et al.
Cancer Cell|March 12, 2021
Progressive immune dysfunction with advancing disease stage in renal cell carcinomaDavid A Braun, Kelly Street, Kelly P Burke, et al.
Pageof 5